SUBSTIPHARM

Substipharm is a privately held pharmaceutical Group with a global vision and a local approach. Established in 1995 and headquartered in France, the company has a strong presence in the manufacturing and pharmaceutical industries. Substipharm operates in over 60 countries, developing, supplying, and commercializing a diverse portfolio of pharmaceuticals, which includes more than 60 different molecules and over 40 ongoing projects in its development pipeline.

The company's portfolio encompasses mature brands, generics, over-the-counter (OTC) pharmaceuticals, difficult-to-develop medicines, and value-added presentations. Additionally, Substipharm has a successful line of biological products, including vaccines. Although specific details of the last investment and the investors involved are not available at this time, Substipharm's robust product portfolio and global reach position it as an attractive potential investment opportunity for venture capital firms seeking exposure to the pharmaceutical sector.